Management of cancer pain

Seminars in Oncology

Volumn 32, Issue 2, 2005, Pages 179-193

  Levy, Michael H ^a   Samuel, Thomas A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT; BISACODYL; CALCITONIN; CHOLINE MAGNESIUM TRISALICYLATE; CODEINE; CORTICOSTEROID; DOCUSATE SODIUM; FENTANYL; HYDROCODONE; HYDROMORPHONE; IBUPROFEN; LEVORPHANOL; LIDOCAINE; MACROGOL; MAGNESIUM CITRATE; MAGNESIUM HYDROXIDE; METHADONE; MEXILETINE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PAMIDRONIC ACID; PARACETAMOL; PETHIDINE; SENNOSIDE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ABDOMINAL CRAMP; ANALGESIA; ARTHRITIS; AUTONOMIC DYSFUNCTION; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PATIENT; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG INDICATION; HOT FLUSH; HUMAN; INFLAMMATION; INSOMNIA; MEDICAL ASSESSMENT; MYOPATHY; NAUSEA; NERVE BLOCK; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; OPIATE ADDICTION; OSTEOPOROSIS; POSTOPERATIVE PAIN; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; SPINAL CORD COMPRESSION; SWEAT GLAND DISEASE; TITRIMETRY; TREATMENT PLANNING; TREMOR; VOMITING; WITHDRAWAL SYNDROME;

AGROBACTERIUM; ARABIDOPSIS; RHIZOBIUM;

EID: 33645580619     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.02.004     Document Type: Article

References (143)

1. A. Jemal, T. Murray, E. Ward Cancer statistics, 2005 CA Cancer J Clin 55 2005 10 30
2. C.S. Cleeland, R. Gonin, A.K. Hatfield Pain and its treatment in outpatients with metastatic cancer N Engl J Med 330 1994 592 596
3. K.M. Foley, H. Gelband Improving Palliative Care for Cancer Summary and Recommendations 2001 Academic Press Washington, DC
4. A. Jacox, D.B. Carr, R. Payne Management of Cancer Pain Clinical Practice Guideline. No. 9 (AHCPR publication no. 94-0592) 1994 Agency for Health Care Policy and Research Rockville, MD
5. C. Miaskowski, J. Cleary, R. Burney Guideline for the Management of Cancer Pain in Adults and Children, APS Clinical Practice Guidelines Series, No. 3 2005 American Pain Society Glenview, IL
6. N. Sykes M. Fallon R. Patt Clinical Pain Management Cancer Pain 2003 Oxford University Press New York, NY
7. S. Grond, D. Zech, C. Diefenbach Prevalence and pattern of symptoms in patients with cancer pain A prospective evaluation of 1635 cancer patients referred to a pain clinic J Pain Symptom Manage 9 1994 372 382
8. N. Coyle, J. Adelhardt, K.M. Foley Character of terminal illness in the advanced cancer patient Pain and other symptoms during the last four weeks of life J Pain Symptom Manage 5 1990 83 93
9. M.H. Levy Integration of pain management into comprehensive cancer care Cancer 63 suppl 1989 2328 2335
10. P. Kim Interventional cancer pain therapies Semin Oncol 32 2005 194 199
11. M.H. Levy, S.C. Cohen Sedation for the relief of refractory symptoms A fine intentional line Semin Oncol 32 2005 237 246
12. P. Rousseau Palliative sedation in the management of refractory symptoms J Support Oncol 2 2004 181 186
13. N.I. Cherny The Use of Sedation in the Management of Refractory Pain. Principles and Practices of Supportive Oncology Update, vol. 3 2000 Lippincott Williams & Wilkins New York, NY 1 11
14. J.D. Cowan, D. Walsh Terminal sedation in palliative medicine--Definition and review of the literature Support Care Cancer 9 2001 403 407
15. L. Snyder, D.P. Sulmasy Physician-assisted suicide Ann Intern Med 135 2001 209 216
16. J.C. Ballantyne Chronic pain following treatment for cancer The role of opioids Oncologist 8 2003 567 575
17. N.I. Cherny The pharmacologic management of cancer pain Oncology 18 2004 1499 1515
18. M.H. Levy Pharmacologic management of cancer pain Semin Oncol 21 1994 718 739
19. M.H. Levy Pharmacologic treatment of cancer pain N Engl J Med 335 1996 1124 1132
20. Principles of Analgesic Use in the Treatment of Acute Pain and Chronic Cancer Pain Ed. 5 2003 American Pain Society Glenview, IL
21. D. Doyle G.W.C. Hanks N. MacDonald Oxford Textbook of Palliative Medicine (ed 3) 2003 Oxford University Press Oxford, England
22. A. Berger R.P. Portenoy D. Weisman Principles and Practice of Palliative Care and Supportive Oncology 2002 Lippincott-Raven Philadelphia, PA
23. D.C. Turk, E.S. Monarch, A.D. Williams Cancer patients in pain Considerations for assessing the whole person Hematol Oncol Clin North Am 16 2002 511 525
24. R.C. Serlin, T.R. Mendoza, Y. Nakamura When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function Pain 61 1995 277 284
25. A. Caraceni, R.K. Portenoy An international survey of cancer pain characteristics and syndromes Pain 82 1999 263 274
26. E. Eisenberg Post-surgical neuralgia Pain 111 2004 3 7
27. S.L. Bartusch, B.J. Sanders, J.G. D'Alessio Clonazepam for the treatment of lancinating phantom limb pain Clin J Pain 12 1996 59 62
28. C. Zaza, N. Baine Cancer pain and psychosocial factors A critical review of the literature J Pain Symptom Manage 24 2002 526 542
29. S.D. Passik, F.K. Portenoy, P.L. Ricketts Substance abuse issues in cancer patients Oncology 12 1998 517 521
30. Cancer Pain Guideline Panel. Cancer Pain Guidelines, Version 1.2004. Philadelphia, PA. National Comprehensive Cancer Network, [ www.nccn.org ], 2004
31. Savage S, Covington E, Heit H,, et al. Definitions related to the use of opioids for the treatment of pain: A consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Glenview, IL, 2001
32. J.C. Ballantyne, J. Mao Opioid therapy for chronic pain N Engl J Med 349 2003 1943 1953
33. A.M. Gilson, K.M. Ryan, D.E. Joranson A reassessment of trends in the medical use and abuse of opioid analgesics and the implications for diversion control 1997-2002 J Pain Symptom Manage 28 2004 176 188
34. S.D. Passik, K.L. Kirsh, L. Whitcomb Pain clinicians' rankings of aberrant drug-taking behaviors J Pain Palliat Care Pharmacother 16 2002 39 49
35. E. McNicol, S. Strassels, L. Goudas Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain A systematic review J Clin Oncol 22 2004 1975 1992
36. A.J. Makin, J. Wendon, R. Williams A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993) Gastroenterology 109 1995 1907 1916
37. F.V. Schiodt, F.A. Rochling, D.L. Casey Acetaminophen toxicity in an urban county hospital N Engl J Med 337 1997 1112 1117
38. L. Simon, A. Jacox, M. Caudill-Slosberg Guideline for the Management of Pain in Osteoarthritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis 2002 American Pain Society Glenview, IL
39. M. Valentini, R. Cannizzaro, M. Poletti Non-steroidal anti-inflammatory drugs for cancer pain comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage J Clin Oncol 13 1995 2637 2642
40. D. Graham, N. Agrawal, D. Campbell Ulcer prevention in long-term use of nonsteroidal anti-inflammatory drugs. Results of a double-blind, randomized, multice4nter, active- and placebo-controlled study of misoprostol vs. lansoprazole Arch Intern Med 162 2002 169 175
41. J.J. Stuart, E.J. Pisko Choline magnesium trisalicylate does not impair platelet aggregation Pharmacotherapeutics 2 1981 547 551
42. J.R. Johnson, A.J. Miller The efficacy of choline magnesium trisalicylate (CMT) in the management of metastatic bone pain A pilot study Palliat Med 8 1994 129 135
43. D.W. Clark, D. Layton, S.A. Shakir Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology Drug Saf 27 2004 427 456
44. US Food and Drug Administration: Public Health Advisory. Non-steroidal Anti-inflammatory Drug Products (NSAIDS). DA/Center for Drug Evaluation and Research. Rockville, MD, [ www.fda.gov/cder ], December 23, 2004
45. D.H. Solomon, S. Schneeweis, R.J. Glynn Relationship between selective cyclo-oxygenase-2 inhibitors and acute myocardial infarction in older adults Circulation 109 2004 2068 2073
46. W.B. White, G. Faich, J.S. Borer Cardiovascular thrombotic events in arthritis trials of cyclo-oxygenase-2 inhibitor Celecoxib Am J Cardiol 92 2003 411 418
47. A. Sunshine New clinical experience with tramadol Drugs 47 suppl 1 1994 8 18
48. C.H. Wilder-Smith, J. Schimke, B. Osterwalder Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain Ann Oncol 5 1994 141 146
49. A. Stubhaug, J. Grimstad, H. Breivik Lack of analgesic effect of 50 and 100 mg oral tramadol after orthopedic surgery A randomized, double-blind, placebo and standard active drug comparison Pain 62 1995 111 118
50. J. Desmeules, M.-P. Gascon, P. Dayer Impact of environmental and genetic factors on codeine analgesia Eur J Clin Pharmacol 41 1991 23 26
51. S.H. Sindrup, L. Arendt-Nielsen, K. Brosen The effect of quinidine on the analgesic effect of codeine Eur J Clin Pharmacol 42 1992 587 591
52. B.S. Galer, N. Coyle, G.W. Pasternak Individual variability in the response to different opioids Report of five cases Pain 49 1992 87 91
53. N. MacDonald, L. Der, S. Allan, P. Champion Opioid hyperexcitability The application of alternate opioid therapy Pain 53 1993 353 355
54. N.D. de Stoutz, E. Bruera, M. Suarez-Almazor Opioid rotation for toxicity reduction in terminal cancer patients J Pain Symptom Manage 10 1995 378 384
55. M.P. Davis, D. Walsh Methadone for relief of cancer pain A review of pharmacokinetics, pharmacodynamics, drug interactions, and protocols of administration Support Care Cancer 9 2001 73 83
56. E. Bruera, J. Pereira, S. Watanbe Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine Cancer 78 1996 852 857
57. E. Bruera, J.L. Palmer, S. Bosniak Methadone versus morphine as a first-line strong opioid for cancer pain A randomized, double-blind study J Clin Oncol 22 2004 185 192
58. J.W. Finn, T.D. Walsh, N. MacDonald Placebo-blinded study of morphine sulfate sustained-release tablets and immediate-release morphine sulfate solution in outpatients with chronic pain due to advanced cancer J Clin Oncol 11 1993 967 972
59. E. Kalso, A. Vainio Morphine and oxycodone hydrochloride in the management of cancer pain Clin Pharmacol Ther 47 1990 639 646
60. P.A. Glare, T.D. Walsh Dose-ranging study of oxycodone for chronic pain in advanced cancer J Clin Oncol 11 1993 973 978
61. M.H. Levy Advancement of opioid analgesia with controlled-release oxycodone Eur J Pain 5 suppl A 2001 113 116
62. R. Swanton, B. Buckley Long-term efficacy and safety of once-daily oral extended-release hydromorphone J Clin Pharmacol 22 2002 1068 (abstr)
63. C. Wright, M.G. Shi, C. Colonnese Efficacy and safety of an oral 24-hour extended-release hydromorphone formulation for the relief of persistent nonmalignant pain Pain Med 5 2004 115 (abstr)
64. S.D. Roy, G.L. Flynn Solubility and related physicochemical properties of narcotic analgesics Pharm Res 5 1988 580 586
65. OxyContin Its Use and Abuse. Hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, August 28, 2001. 2001 US Government Printing Office Washington, DC Serial No. 107-54
66. M.P. Davis, J. Varga, D. Dickerson Normal-release and controlled-release oxycodone Pharmacokinetics, pharmacodynamics, and controversy Support Care Cancer 11 2003 84 92
67. B. Donner, M. Zenz, M. Tryba Direct conversion from oral morphine to transdermal fentanyl A multicenter study in patients with cancer pain Pain 64 1996 527 534
68. S. Ahmedzai, D. Brooks Transdermal fentanyl versus sustained-release oral morphine in cancer pain Preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group J Pain Symptom Manage 13 1997 254 261
69. R. Payne Factors influencing quality of life in cancer patients The role of transdermal fentanyl in the management of pain Semin Oncol 25 suppl 7 1998 47 53
70. C.A. Kornick, J. Santiago-Palma, N. Khojainova A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl Cancer 92 2001 3056 3061
71. J.B. Streisand, M.A. Busch, T.D. Egan Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate Anesthesiology 88 1998 305 309
72. J.M. Christie, M. Simmonds, R. Patt Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain J Clin Oncol 16 1998 3238 3245
73. R.K. Portenoy, R. Payne, P. Coluzzi Oral transmucosal fentanyl citrate (OFTC) for the treatment of break through pain in cancer patients A controlled dose titration study Pain 79 1999 303 312
74. F.J. Brescia, R.K. Portenoy, M. Ryan Pain, opioid use, and survival in hospitalized patients with advanced cancer J Clin Oncol 10 1992 149 155
75. K.M. Foley Changing Concepts of tolerance to opioids What the cancer patient has taught us C.R. Chapman K. Foley Current and Emerging Issues in Cancer Pain Research and Practice 1993 Raven New York, NY 331 350
76. B.R. Ferrell, H. Griffith Cost issues related to pain management Report from the Cancer Pain Panel of the Agency for Health Care Policy and Research J Pain Symptom Manage 9 1994 221 234
77. M.P. Davis, D. Walsh, S.B. LeGrand Symptom control in cancer patients The clinical pharmacology and therapeutic role of suppositories and rectal suspensions Support Care Cancer 10 2002 117 138
78. A. Broomhead, R. Kerr, W. Tester Comparison of a once-a-day sustained-release morphine formulation with standard oral morphine treatment for cancer pain J Pain Symptom Manage 14 1997 63 73
79. A. Broomhead, R. West, G. Kadirgamanathan Comparative bioavailability of sustained-release morphine sulfate capsules versus pellets Clin Drug Invest 14 1997 137 145
80. L. Eliot, J. Butler, J. Davane Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation Clin Ther 24 2002 260 268
81. R.K. Portenoy, A. Sciberras, L. Eliot Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain J Pain Symptom Manage 23 2002 292 300
82. I.G. Kerr, M. Sone, D. Deangelis Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients Ann Intern Med 188 1988 554 557
83. N. Coyle, N.I. Cherny, R.K. Portenoy Subcutaneous opioid infusions at home Oncology 8 1994 21 27
84. D.E. Moulin, J.H. Kreeft, N. Murray-Parsons Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain Lancet 337 1991 465 468
85. G. Bennett, K. Burchiel, E. Buchser Clinical guidelines for intraspinal infusion: Report of an expert panel. PolyAnalgesic Consensus Conference J Pain Symptom Manage 20 2000 S37 S43
86. T.J. Smith, P.S. Staats, T. Deer Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain Impact on pain, drug-related toxicity, and survival J Clin Oncol 20 2002 4040 4049
87. S.M. Walker, L.C. Goudas, M.J. Cousins Combination spinal analgesic chemotherapy A systemic review Anesth Analg 95 2002 674 715
88. L.L. Ackerman, K.A. Follett, R.W. Rosenquist Long term outcomes during treatment of chronic pain with intrathecal clonidine or clonidine/opioid combinations J Pain Symptom Manage 26 2003 668 677
89. P.S. Staats, T. Yearwood, S.G. Charapata Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. A randomized controlled trial JAMA 291 2003 63 70
90. N. Cherny, C. Ripamonti, J. Pereira Strategies to manage the adverse effects of oral morphine An evidence-based report J Clin Oncol 19 2001 2542 2554
91. M.H. Levy Management of opioid-induced bowel dysfunction J Natl Compr Cancer Network 1 suppl 3 2003 S22 S26
92. E. McNicol, N. Horowicz-Mehler, R.A. Fisk Management of opioid side-effects in cancer-related and chronic non-cancer pain A systematic review J Pain 4 2003 231 256
93. C.M. Herndon, K.C. Jackson, P.A. Hallin Management of opioid-induced gastrointestinal effects in patients receiving palliative care Pharmacotherapy 22 2002 240 250
94. M.B. Wilwerding, C.L. Loprinzi, M.A. Mailliard A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics Support Care Cancer 3 1995 135 138
95. J. Sawynok, T.L. Yaksh Caffeine as an analgesic adjuvant A review of pharmacology and mechanisms of action Pharmacol Rev 45 1993 43 85
96. L. Webster Modafanil treatment of opioid-induced sedation Pain Med 4 2003 135 140
97. J.H. Eisele Jr, E.J. Grigsby, G. Dea Clonazepam treatment of myoclonic contractions associated with high-dose opioids Case report Pain 49 1992 231 232
98. A.M. Davis, C.E. Inturrisi d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia J Pharmacol Exp Ther 289 1999 1048 1053
99. F. DeConno, L. Groff, D. Brunelli Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients J Clin Oncol 14 1996 2836 2842
100. D. Lussier, A.G. Huskey, R.K. Portenoy Adjuvant analgesics in cancer pain management Oncologist 9 2004 571 591
101. S. Watanabe, E. Bruera Corticosteroids as adjuvant analgesics J Pain Symptom Manage 9 1994 442 445
102. S. Mercadante, F. Fulfaro, A. Casuccio The use of corticosteroids in home palliative care Support Care Cancer 9 2001 386 389
103. C.P. Watson The treatment of neuropathic pain Antidepressants and opioids Clin J Pain 16 suppl 2 2000 49 55
104. H.J. McQuay, M. Tramer, B.A. Nye A systematic review of antidepressants in neuropathic pain Pain 68 1996 217 227
105. R.H. Dworkin, M. Backonja, M.C. Rowbotham Advances in neuropathic pain Diagnosis, mechanisms, and treatment recommendations Arch Neurol 60 2003 1524 1534
106. P.V. Rasmussen, T.S. Jensen, S.H. Sindrup TDM-based imipramine treatment in neuropathic pain Ther Drug Monit 26 2004 352 360
107. M.B. Max, S.A. Lynch, J. Muir Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy N Engl J Med 326 1992 1250 1256
108. T. Tasmuth, B. Hartel, E. Kalso Venlafaxine in neuropathic pain following treatment of breast cancer Eur J Pain 6 2002 17 24
109. S.H. Sindrup, F.R.W. Bach, C. Madsen Venlafaxine versus imipramine in painful polyneuropathy. A randomized controlled trial Neurology 60 2003 1284 1289
110. M. Fava, C.H. Mallinckrodt, M.J. Detke The effect of duloxetine on painful physical symptoms in depressed patients Do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 65 2004 521 531
111. M.I. Bennett, K.H. Simpson Gabapentin in the treatment of neuropathic pain Palliat Med 18 2004 5 11
112. M.S. Chong, Z.H. Bajwa Diagnosis and treatment of neuropathic pain J Pain Symptom Manage 25 suppl 2003 4 11
113. M. Namaka, C.R. Gramlich, D. Ruhlen A treatment algorithm for neuropathic pain Clin Ther 26 2004 951 979
114. M.M. Backonja Anticonvulsants (antineuropathics) for neuropathic pain syndromes Clin J Pain 16 suppl 2 2000 67 72
115. A. Dejgard, P. Petersen, J. Kastrup Mexiletine for treatment of chronic painful diabetic neuropathy Lancet 1 1988 9 11
116. C. Chabal, L. Jacobson, A. Mariano The use of oral mexiletine for the treatment of pain after peripheral nerve injury Anesthesiology 76 1992 513 517
117. D.L. Tanelian, R.A. Victory Sodium channel-blocking agents their use in neuropathic pain conditions Pain Forum 4 1995 75 80
118. P. Sloan, M. Basta, P. Storey Mexiletine as an adjuvant analgesic for the management of neuropathic cancer pain Anesth Analg 89 1999 760 761
119. B.S. Galer, M.C. Rowbotham, J. Perander Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch Results of an enriched enrollment study Pain 80 1999 533 538
120. A.R. Gammaitoni, N.A. Alvarez, B.S. Galer Safety and tolerability of lidocaine patch 5%, a targeted peripheral analgesic A review of the literature J Clin Pharmacol 43 2003 111 117
121. G.H. Fromm Baclofen as an adjuvant analgesic J Pain Symptom Manage 9 1994 500 509
122. J.P. Harner, B. Larson Pain relief from Baclofen analgesia in neuropathic pain patients who failed opioid pharmacotherapy Case report J Pain Palliat Care Pharmacother 16 2002 61 64
123. M.S. Chong, S.E. Libretto The rationale and use of topiramate for treating neuropathic pain Clin J Pain 19 2003 59 69
124. R.L. Schmid, A.N. Sandler, A. Katz Use and efficacy of low-dose ketamine in the management of acute postoperative pain A review of current techniques and outcomes Pain 82 1999 111 125
125. E.J. Fitzgibbon, P. Hall, C. Schroeder Low dose ketamine as an analgesic adjuvant in difficult pain syndromes A strategy for conversion from parenteral to oral ketamine J Pain Symptom Manage 23 2002 165 170
126. R.F. Bell, C. Eccleston, E. Kalso Ketamine as adjuvant to opioids for cancer pain. A qualitative systemic review J Pain Symptom Manage 26 2003 867 875
127. D.J. Bloomfield Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review J Clin Oncol 16 1998 1218 1225
128. R.L. Theiriault, A. Lipton, G.N. Hortabagyi Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions A randomized, placebo-controlled trial J Clin Oncol 17 1999 846 854
129. F. Saad, D.M. Gleason, R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
130. L.S. Rosen Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors Semin Oncol 29 suppl 21 2002 28 32
131. A. Skerjanec, J. Berenson, C. Hsu The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function J Clin Pharmacol 43 2003 154 162
132. C. Gennari, S.M. Chierchetti, M. Piolini Analgesic activity of salmon and human calcitonin against cancer pain A double-blind, placebo-controlled clinical study Curr Ther Res 38 1985 298 303
133. A. Roth, K. Kolaric Analgesic activity of calcitonin in patients with pain from osteolytic metastases of breast cancer Oncology 43 1986 283 287
134. H. Jaeger, C. Maier Calcitonin in phantom limb pain a double-blind study Pain 48 1992 21 27
135. J. Szanto, N. Ady, S. Jozsef Pain killing with calcitonin nasal spray in patients with malignant tumors Oncology 49 1992 180 182
136. R.G. Robinson, D.F. Preston, M. Schiefelbein Strontium-89 therapy for the palliation of pain due to osseous metastases JAMA 274 1995 420 424
137. C.L. Rogers, B.L. Speiser, P.C. Ram Efficacy and toxicity of intravenous strontinum-89 for symptomatic osseous metastases J Brachyther Int 14 1998 133 142
138. A.S. Alberts, B.J. Smit, W.K.A. Louw Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone Radiother Oncol 43 1997 175 179
139. A.N. Serafine, S.J. Houston, I. Resche Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam A double-blind, placebo-controlled clinical trial J Clin Oncol 16 1998 1574 1581
140. S. Mercadante, C. Ripamonti, A. Casuccio Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction Support Care Cancer 8 2000 188 191
141. C. Ripamonti, S. Mercadante, I. Gnoff Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes A prospective randomized trial J Pain Symptom Manage 19 2000 23 34
142. A. Jatoi, K.C. Podratz, P. Gill Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer J Support Oncol 2 2004 323 337
143. C. Ripamonti, S. Mercadante How to use octreotide for malignant bowel obstruction J Support Oncol 2 2004 357 364